The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d’Hebron Institute of Oncology phase I program cohort.
 
Enrique Sanz-Garcia
No Relationships to Disclose
 
Elena Elez
No Relationships to Disclose
 
Guillem Argiles
No Relationships to Disclose
 
Javier Hernandez-Losa
No Relationships to Disclose
 
Ana Vivancos
No Relationships to Disclose
 
Debora Moreno
No Relationships to Disclose
 
Teresa Macarulla
No Relationships to Disclose
 
Jaume Capdevila
No Relationships to Disclose
 
Maria Alsina
No Relationships to Disclose
 
Tamara Sauri
No Relationships to Disclose
 
Cinta Hierro
No Relationships to Disclose
 
Analia Azaro
No Relationships to Disclose
 
Cristina Cruz Zambrano
No Relationships to Disclose
 
Marta Vilaro
No Relationships to Disclose
 
Jose Jimenez
No Relationships to Disclose
 
Stefania Landolfi
No Relationships to Disclose
 
Paolo Nuciforo
No Relationships to Disclose
 
Santiago Ramon y Cajal
No Relationships to Disclose
 
Jordi Rodon
No Relationships to Disclose
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Taiho Pharmaceutical